By judgment of 23 January 2018, the Court of Justice of the EU addressed the competition law implications of off-label uses of medicines concerning the definition of the relevant market, ancillary restrictions to licensing agreements, and the dissemination of misleading information on risks under conditions of scientific uncertainty.

Competition law implications of off label uses of medicines: F. Hoffmann La Roche Ltd and others v Autorità Garante della Concorrenza e del Mercato (AGCM)

A. Parziale
2018-01-01

Abstract

By judgment of 23 January 2018, the Court of Justice of the EU addressed the competition law implications of off-label uses of medicines concerning the definition of the relevant market, ancillary restrictions to licensing agreements, and the dissemination of misleading information on risks under conditions of scientific uncertainty.
2018
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11382/534522
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
social impact